(Press-News.org)
Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with the deadliest form of blood cancer.
The federal Food and Drug Administration has approved the drug ziftomenib for patients with recurring or treatment-resistant acute myeloid leukemia who have a mutation in the NPM1 gene. The new medication, taken by mouth once daily, offers a potential treatment for patients who otherwise have no good options.
The drug arose from many years of research by Jolanta Grembecka, PhD, and Tomasz Cierpicki, PhD, who began the work in 2007 as research assistant professors in UVA’s Department of Molecular Physiology and Biological Physics, working closely with John Bushweller, PhD, their former postdoctoral mentor. In 2009, both Grembecka and Cierpicki moved to the University of Michigan, where they are professors in the Department of Pathology.
“Ziftomenib is a long-awaited and desperately needed new option for patients for whom other treatments have failed – for patients left with no hope. It’s a wonderful achievement by Drs. Grembecka and Cierpicki,” said Mark Esser, PhD, the head and chief scientific officer of UVA’s Paul and Diane Manning Institute of Biotechnology. “UVA has founded the Manning Institute specifically to advance exactly this type of important research. We are accelerating the development of new treatment and cures for the most complex and difficult diseases to benefit patients everywhere.”
About Acute Myeloid Leukemia
Acute myeloid leukemia is a particularly deadly blood cancer primarily seen in people over the age of 68. More than 22,000 Americans develop the condition each year, and more than 11,000 die, according to the American Cancer Society. Overall, the disease accounts for about 1 in 3 cases of blood cancer.
“Acute myeloid leukemia is a very aggressive blood cancer with poor clinical outcomes,” Grembecka said. “Seeing our pioneering work on menin inhibitors evolve into an FDA-approved treatment for leukemia patients is extremely rewarding. It is remarkable to witness the direct impact of our research, which resulted in a drug that benefits leukemia patients. This is an achievement we could only dream of, and now it’s a reality.”
Cierpicki and Grembecka’s work at UVA and Michigan produced foundational discoveries that were licensed to Kura Oncology in 2014. The new drug has been developed by collaboration of Grembecka and Cierpicki with Kura Oncology and brought to market under the brand name Komzifti by Kura and pharmaceutical group Kyowa Kirin.
The drug works by disrupting interactions of a cellular protein, menin, that drive leukemia cell growth and survival. It allows cells to mature into white blood cells instead of becoming cancerous.
“To develop menin inhibitors, we had to pioneer an entirely new area of research – producing the human protein, creating robust biochemical assays, conducting high-throughput screening and solving the crystal structure of menin,” Cierpicki said. “We accomplished this at a time when the pharmaceutical industry remained skeptical that targeting protein-protein interactions was even feasible.”
Grembecka and Cierpicki’s collaboration with Kura led to the discovery of ziftomenib, which won FDA approval based on the results of clinical trials that began in 2019. A new treatment option was needed so badly that the federal agency gave ziftomenib a priority review.
“It is immensely gratifying to see the work of Drs. Grembecka and Cierpicki have this amazing impact for patients,” said Bushweller, part of UVA Comprehensive Cancer Center. “Their success portends a future with more such targeted agents and successes that dramatically improve cancer care.”
Ongoing trials are exploring ziftomenib’s potential to work in combination with other treatments to target both leukemia and solid tumors.
“Drug development has traditionally been a long and slow process,” UVA’s Esser explained. “But many patients don’t have time to wait. The Manning Institute is committed to developing new treatments quickly and safely so we can get them to the patients who need them most.”
“It’s always exciting to see UVA research produce important new options such as ziftomenib for patients,” Esser said. “Now we are positioned to make that happen faster.”
About the Research
Grembecka and Cierpicki’s work has been supported by the National Institutes of Health, the American Cancer Society and Blood Cancer United, formerly known as the Leukemia & Lymphoma Society.
The researchers, the University of Michigan and UVA all have a financial interest in ziftomenib.
To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog at http://makingofmedicine.virginia.edu.
END
The American College of Lifestyle Medicine (ACLM) has published a position paper calling for the implementation of lifestyle medicine as a high-value care solution that delivers on the Quintuple Aim—better health outcomes, higher patient and clinician satisfaction, greater health equity, and lower costs.
The paper includes five position statements asserting that lifestyle medicine—a rapidly growing medical specialty focused on evidence-based lifestyle interventions to treat, reverse and prevent chronic disease—offers a scalable and sustainable approach to address the nation’s ...
BUFFALO, NY — November 25, 2025 — A new research paper was published in Volume 17, Issue 10 of Aging-US on October 13, 2025, titled “Hospitalization with infections and risk of Dementia: a systematic review and meta-analysis.”
This large-scale meta-analysis, led by first author Wei Yu Chua from the National University of Singapore and corresponding author Eng-King Tan from the National Neuroscience Institute and Duke-NUS Medical School in Singapore, shows that adults hospitalized ...
WASHINGTON—Women with persistent thyroid hormone imbalance across pregnancy may be at an increased risk of having children with autism, according to a new study published in The Journal of Clinical Endocrinology & Metabolism.
Maternal thyroid hormones are essential for fetal neurodevelopment. Gestational thyroid imbalance has been associated with atypical neurodevelopment, including increased risk of autism spectrum disorder (ASD). Autism is a complex neurodevelopmental condition that affects how a person communicates, interacts with others and experiences the world.
“We ...
Global challenges necessitate cooperation beyond national borders. Prosociality—the tendency to share with and value the outcomes of others—can help achieve this objective. While it is well-established that people favor their own compatriots, people also display substantial prosociality toward individuals from other nations, though not all foreigners are treated equally.
Vanessa Clemens and colleagues invited 6,182 participants from 25 nations to take part in a sharing game with individuals from each of the participating nations. Each person received 150 “Talers” — a made-up currency — and chose between different ways of sharing the ...
If people do not observe inequality, they are less likely to favor policies that redistribute wealth, such as taxation—but they are also more satisfied with their lot, according to online experiments involving 1,440 US-based participants. Milena Tsvetkova and colleagues developed a model simulating how network structure affects perception of inequality and tested its predictions through an online experiment where participants voted on tax rates. In the experiment, participants were randomly assigned as "rich" (with scores around ...
The same personalized algorithms that deliver online content based on your previous choices on social media sites like YouTube also impair learning, a new study suggests.
Researchers found that when an algorithm controlled what information was shown to study participants on a subject they knew nothing about, they tended to narrow their focus and only explore a limited subset of the information that was available to them.
As a result, these participants were often wrong when tested on the information they were supposed to learn – but were still overconfident in their incorrect answers.
The ...
Note: December 1-5 is Older Driver Safety Awareness Week
When today’s older adults learned to drive, they might have heard the Beatles’ “Drive My Car” or Bruce Springsteen’s “Born to Run” on their car radio’s Top 40 station.
Now, 84% of people age 65 and older drive at least once a week, and 62% drive most days, according to a new University of Michigan national poll.
But less than half of these older drivers have made a plan for a time down the road, when changes ...
Up to 30% of life, by weight, is underground. Seismic activity may renew the energy supply for subterranean ecosystems.
Eric Boyd and colleagues chronicled the ecological changes in subsurface microbial communities that took place after a swarm of small earthquakes rattled the Yellowstone Plateau Volcanic Field in 2021. Subsurface microbial communities are powered by chemical energy gleaned from the interactions between rocks and water. Earthquakes can expose new rocks, release trapped fluids, and alter the flow path of water, together kicking off new reactions and changing the chemical “menu” for subsurface ...
Artificial intelligence (AI) is becoming an integral part of our everyday lives and with that emerges a pressing question: Who should be held responsible, when AI goes wrong? AI lacks consciousness and free-will, which makes it difficult to blame the system for the mistakes. AI systems operate through complex, opaque processes in a semi-autonomous manner. Hence, even though the systems are developed and used by human stakeholders, it is impossible for them to predict the harm. The traditional ethical frameworks thus fail to explain who is responsible for these harms, leading to the so-called responsibility gap in AI ethics.
A recent study by Dr. Hyungrae Noh, an Assistant ...
Perovskites—a class of compounds with a unique ABX3 structure and high temperature stability—are promising materials for energy conversion. In recent years, they have been utilized in photovoltaic systems. They exhibit excellent performance in solid oxide fuel cells and organic reactions such as oxidative coupling of methane (OCM) for the production of ethane and ethylene.
Notably, BaTiO3 is a promising perovskite with applications in fields including ferroelectricity, piezoelectricity, and semiconductivity. It possesses a flexible lattice and rich defect chemistry, making it suitable for structural modifications via doping for enhanced functional performance. Furthermore, ...
